Pilot Study of RR-HNK in OCD ((HNKO))

The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.

Randomized, parallel-group, triple-masked Phase I/II trial comparing single IV infusions of 0.25 mg/kg and 0.5 mg/kg RR-HNK versus sterile saline placebo in adults with OCD; EEG and computerized behavioural tests acquired before and after infusion.